| Date | Title | Description |
| 06.09.2024 | Entrada Therapeutics Announces Recipients of Second Annual Diversity, Representation, Equity and Advocacy MatterS (DREAMS) Grant Program | - Second annual DREAMS Grant Program awards $25,000 each to three U.S.-based non-profit organizations working to achieve greater equality for those living with Duchenne -
- Announced in celebration of World Duchenne Awareness Day, grants ar... |
| 24.07.2024 | cTAP Study Indicates Duchenne Muscular Dystrophy Clinical Trial Enrollment Criteria Should Expand Beyond Ambulatory Status | Study Co-Funded by CureDuchenne and cTAP Highlights Need for More Specific Enrollment Criteria That Could Increase Patient Participation and Drive More Comprehensive Therapeutic Evaluation
CAMBRIDGE, Mass., July 24, 2024 /PRNewswire/ -- The... |
| 12.04.2023 | CureDuchenne Partners with PicnicHealth to Advance Research and Simplify Patient Experience by Incorporating Electronic Health Records into Data-Integrated Biobank | Comprehensive Real-World Data will Enhance CureDuchenne Link as a Unique Resource to Accelerate Research Toward a Cure for Duchenne Muscular Dystrophy
CureDuchenne, a global nonprofit committed to finding and funding a cure for Duchenne mus... |
| 22.09.2021 | DMD: Charting the Path for New Therapeutics and Better Care | Published On: 09.22.21
DMD: Charting the Path for New Therapeutics and Better Care Featured
Dear colleagues and friends,
Thank you for participating in our global webinar, "Duchenne Muscular Dystrophy: Charting the Path for New Therape... |
| 22.07.2021 | Cureduchenne Launches Innovative Supplemental Newborn Screening Initiative Offering Opportunity for Early Diagnosis of Rare, Fatal Disease | |
| 18.06.2021 | Cureduchenne Launches Next-generation Data-sharing Platform To Accelerate A Cure For Duchenne And Becker Muscular Dystrophy | |
| 18.03.2021 | CureDuchenne Hosts Webinar on COVID-19 Vaccines to Educate Duchenne Community, Alongside Clinical, Scientific and Regulatory Experts | |
| 14.01.2021 | Cureduchenne Launches Initiative To Prioritize Duchenne Community Needs For COVID-19 Vaccine Rollout | |
| 10.11.2020 | CureDuchenne Ventures Announces Funding Of Mesentech, Inc. Within A Funding Collaboration With The Charles H. Hood Foundation | |
| 25.09.2020 | CureDuchenne Congratulates Dyne Therapeutics On Its Initial Public Offering | |
| 17.09.2019 | Boulder’s Edgewise Therapeutics closes $50 million Series B financing | Edgewise Therapeutics, a Boulder company working to develop new therapies for treating patients with debilitating musculoskeletal disease, announced the closing of a $50 million Series B financing round on Tuesday.
The funding will help the... |
| 08.02.2019 | Why my patient advocacy organization is investing in CRISPR | In last year’s action film “Rampage,” which featured Dwayne “The Rock” Johnson, CRISPR gene-editing technology turns a gorilla, a wolf, and a crocodile into monsters the size of skyscrapers that destroy Chicago.
If you missed the movie, you... |
| 17.10.2018 | Avidity Biosciences Receives Equity Investment from CureDuchenne | Avidity Biosciences, a La Jolla, CA-based biotech company advancing a new class of precision medicines based upon antibody-oligonucleotide conjugates, received an equity investment from CureDuchenne.
The amount of the deal was not disclosed... |
| 27.02.2017 |
CureDuchenne Ventures Backs Exonics Therapeutics
| Newport Beach-based investment fund CureDuchenne Ventures, which is a subsidiary of nonprofit CureDuchenne, announced this morning that it has invested $5M in a seed funding round for Exonics Therapeutics, a biotech startup which is focused... |
| 01.08.2016 |
CureDuchenne Ventures Gets Exit At Bamboo Therapeutics
| Newport Beach-based CureDuchenne Ventures, the venture investment arm of nonprofit medical foundation CureDuchenne, says it has scored an exit at Bamboo Therapeutics. CureDuchenne invested in the Series A funding for Raleigh, NC-based Bambo... |
| 22.03.2016 | FDA urged to approve Sarepta DMD drug by dozens of medical experts | More than three dozen medical experts are urging the Food and Drug Administration to approve a Sarepta Therapeutics medicine for combating Duchenne muscular dystrophy, a rare disease that causes muscles in boys to stop working and eventuall... |
| 06.01.2016 | RASRx Receives Equity Funding from CureDuchenne Ventures | RASRx, a US-based startup dedicated to developing therapies for rare diseases, received equity funding from CureDuchenne Ventures LLC, a venture philanthropy company that funds research to find a cure for Duchenne muscular dystrophy*.
The a... |
| 30.04.2014 | PennApps Fellows is looking for startups that need interns [Startup Roundup] | WHO’S GETTING FUNDED?
Wharton edtech startup Digipuppets raised $100,000, according to an SEC filing. The startup, which offers finger puppets that children can use with iPad books, was featured on The Today Show in February. It’s not clear... |
| 27.09.2013 | New venture philanthropy initiative will invest in early-stage treatments for Duchenne | CureDuchenne Ventures has already made its first investment in Lexicon Pharmaceuticals. Woodlands, Texas-based Lexicon is running clinical trials of an experimental drug, LX2931, for rheumatoid arthritis but is apparently also exploring the... |
| - | New venture philanthropy initiative will invest in early-stage treatments for Duchenne | The nonprofit CureDuchenne is applying venture capital thinking to early-stage research funding with a new initiative that will support development of treatments for the most common form of lethal muscular dystrophy, Duchenne.
The Californi... |
